Rexgenero Announces Formation of Scientific Advisory Board

Rexgenero Announces Formation of Scientific Advisory Board

Rexgenero Announces Formation of Scientific Advisory Board and Appoints Leading Experts in Cell Therapy, Cardiovascular Diseases and Wound Healing

London, UK, 5 January 2017: Rexgenero Ltd, a clinical stage regenerative medicine company developing advanced cell-based therapeutics, is pleased to announce today the formation of its Scientific Advisory Board (“SAB”) with five key appointments: Professor Jill Belch FRCP, MD (Hons), FMedSci, FRSE, OBE; Dr Marianne Brodmann MD; Professor Keith Harding CBE, FRCGP, FRCP, FRCS; Professor William R. Hiatt MD, FACP, FAHA; and Professor Paul Quax PhD.

The SAB is expected to serve as a strategic network of scientific, medical and clinical experts to Rexgenero as the company progresses the development of its pipeline in Critical Limb Ischemia (CLI) and initiates phase III trials with its lead candidate Rexmyelocel-T (REX-001), an autologous cell therapy. The SAB is also expected to play an integral role for the company in assessing opportunities for its cell-based therapies in other disease areas with unmet medical needs.

For full information download the press release and backgrounds:

REX – SAB Press Release FINAL 050117